Oak Tree,
This doesn't look good for shorts, but who knows, maybe it's not all that was hoped and IMCL will sell-off . . .
>>Bristol-Myers Squibb Co is near a pact to buy a 19.9 percent stake in biotech company ImClone Systems Inc for $1 billion to help the pharmaceutical giant maintain a large role in the development of cancer treatments, the Wall Street Journal's online edition reported on Wednesday.
The board of Bristol-Myers (NYSE:BMY - news) had approved the transaction, the report said. The ImClone (NasdaqNM:IMCL - news) board was scheduled to meet on Wednesday afternoon and a formal announcement could come after the market closed on Wednesday.
A spokesman for Bristol-Myers declined to comment and an ImClone representative could not be reached for comment, the article said.
Bristol-Myers also would pay ImClone $1 billion in so-called milestone payments and it would gain rights to market ImClone's promising IMC-C225, people familiar with the deal said.
ImClone has submitted IMC-C225 to the U.S. Food and Drug Administration for approval to treat colorectal cancer. The New York company is also testing IMC-C225, a monoclonal antibody intended to regulate the growth of cells, to fight other forms of cancer.
According to the newspaper, under the agreement, Bristol-Myers would have marketing rights to C225 in the U.S. and Canada. ImClone immediately would win access to Bristol Myers' sales force.
The deal would be structured as a tender offer, with Bristol-Myers tendering for 19.9 percent of ImClone's shares at a price of $70 each, said the people familiar with the matter.
Shares of ImClone fell $1.59 to $50.01 on Nasdaq on Tuesday.
Analysts have said Bristol-Myers, facing a flurry of patent expirations and generic competition on several drugs, has one of the best sales forces for cancer drugs in the pharmaceutical industry -- marketers that helped make the firm's Taxol treatment the world's top-selling cancer drug.<<
snip
Cheers, Tuck |
